Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.623
−$0.1012 · -13.97%
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Regular session
$0.623
−$0.1012 · -13.97%
Regular session · ET · Market data may be delayed.
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Day range
Current $0.623
52-week range
Current $0.623
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
41
Mixed
Risk
69
High Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Day range
Current $0.623
52-week range
Current $0.623
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | 10.29M USD | 18.68M USD | 21.71M USD | 16.39M USD |
| Selling, general, and administrative | 12.2M USD | 6.48M USD | 3.27M USD | 3.82M USD |
| Operating expenses | 22.5M USD | 25.16M USD | 24.97M USD | 20.21M USD |
| Interest income | 287.71K USD | 222.29K USD | 352.67K USD | 27.03K USD |
| Interest expense | 20.25K USD | −18.72K USD | 43.64K USD | 16.2K USD |
| Depreciation and amortization | — | 25.16M USD | 24.97M USD | 20.21M USD |
| Operating income | −22.5M USD | −25.16M USD | −24.97M USD | −20.21M USD |
| Net income | −22.23M USD | −27.29M USD | −24.74M USD | −20.16M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$21.00
3270.79% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI436.83K0.00%2.3T USD0.03%$379.55-0.39%
Vanguard Extended Market ETFVXF161.19K0.00%95.4B USD0.05%$231.44-0.88%
iShares Micro-Cap ETFIWC26.23K0.00%1.33B USD0.60%$181.13-1.22%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM20K0.01%116.75M USD0.73%$15.8002-1.06%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
